Have we come full circle – or moved forward? The Women's Health Initiative 10 years on

References

• NHLBI Communications Office. NHLBI Stops Trial of Estrogen Plus Progestin Due to Increased Breast Cancer Risk, Lack of Overall Benefit. Embargoed for release Tuesday, July 9, 2002, 9:30 a.m. Eastern Time. July 8, 2002. http://www.nhlbi.nih.gov/new/press/02-07–09.htm
   Google Scholar
• Kolata G. Study Is Halted Over Rise Seen in Cancer Risk. New York Times, July 9, 2002. http://www.nytimes.com/2002/07/09/us/study-is-halted-over-rise-seen-in-cancer-risk.html?pagewanted = all
   Google Scholar
• Hsia J, Langer RD, Manson JE, . Conjugated equine estrogens and coronary disease. Arch Intern Med 2006;166:357–65
   PubMed Web of Science ®Google Scholar
• Rossouw JE, Prentice RL, Manson JE, . Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 2007;297:1465–77
   PubMed Web of Science ®Google Scholar
• Guthrie P. Women React to Finding on Hormone Replacement Therapy. Atlanta Journal-Constitution, 7/10/02. http://www.highbeam.com/doc/1G1 - 88731840.html
   Google Scholar
• Women's Health Initiative Investigators. Protocol for clinical trial and observational study components. WHI manuals: Volume 1 - Study protocol and policies 01/07/03. http://www.whiscience.org/about/manual/manual_1_1.pdf
   Google Scholar
• Writing Group for the Women's Health Initiative. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321–33
   PubMed Web of Science ®Google Scholar
• Nachtigall LE, Nachtigall RH, Nachtigall RD, Beckman EM. Estrogen replacement therapy. II. A prospective study in the relationship to carcinoma and cardiovascular and metabolic problems. Obstet Gynecol 1979;54:74–9
   PubMed Web of Science ®Google Scholar
• Manson JE, Hsia J, Johnson KC, .; Women's Health Initiative Investigators. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003;349:523–34
   PubMed Web of Science ®Google Scholar
• Chlebowski RT, Hendrix SL, Langer RD, .; WHI Investigators. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative randomized trial. JAMA 2003;289:3243–53
   PubMed Web of Science ®Google Scholar
• Hays J, Ockene JK, Brunner RL, .; Women's Health Initiative Investigators. Effects of estrogen plus progestin on health-related quality of life. N Engl J Med 2003;348:1839–54
   PubMed Web of Science ®Google Scholar
• Anderson GL, Limacher M, Assaf AR, .; Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004;291:1701–12
   PubMed Web of Science ®Google Scholar
• Stefanick ML, Anderson GL, Margolis KL, .; Women's Health Initiative Investigators. Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. JAMA 2006;295:1647–57
   PubMed Web of Science ®Google Scholar
• Manson JE, Allison MA, Rossouw JE, .; WHI and WHI-CACS Investigators. Estrogen therapy and coronary-artery calcification. N Engl J Med 2007;356:2591–602
   PubMed Web of Science ®Google Scholar
• Prentice RL, Langer R, Stefanick ML, .; Women's Health Initiative Investigators. Combined postmenopausal hormone therapy and cardiovascular disease: toward resolving the discrepancy between observational studies and the Women's Health Initiative clinical trial. Am J Epidemiol 2005;162:404–14
   PubMed Web of Science ®Google Scholar
• Prentice RL, Langer RD, Stefanick ML, .; Women's Health Initiative Investigators. Am J Epidemiol 2006;163:589–99
   PubMed Web of Science ®Google Scholar
• Prentice RL, Chlebowski RT, Stefanick ML, . Estrogen plus progestin therapy and breast cancer in recently postmenopausal women. Am J Epidemiol 2008;167:1207–16
   PubMed Web of Science ®Google Scholar
• Prentice RL, Chlebowski RT, Stefanick ML, . Conjugated equine estrogens and breast cancer risk in the Women's Health Initiative clinical trial and observational study. Am J Epidemiol 2008;167:1407–15
   PubMed Web of Science ®Google Scholar
• Prentice RL, Manson JE, Langer RD, . Benefits and risks of postmenopausal hormone therapy when it is initiated soon after menopause. Am J Epidemiol 2009;170:12–23
   PubMed Web of Science ®Google Scholar
• Langer RD. Re: Estrogen plus progestin therapy and breast cancer in recently postmenopausal women. Am J Epidemiol 2009;169:784–5
   PubMed Web of Science ®Google Scholar
• Pines A, Sturdee DW, MacLennan AH. Quality of life and the role of menopausal hormone therapy. Climacteric 2012;15:213–16
   PubMed Web of Science ®Google Scholar
• Nappi RE, Davis SR. The use of hormone therapy for the maintenance of urogynecological and sexual health post WHI. Climacteric 2012;15:267–74
   PubMed Web of Science ®Google Scholar
• Hodis HN, P. Collins P, Mack WJ, Lind Schierbeck L. The timing hypothesis for coronary heart disease prevention with hormone therapy: past, present and future in perspective. Climacteric 2012;15:217–28
   PubMed Web of Science ®Google Scholar
• Henderson VW, Lobo RA. Hormone therapy and the risk of stroke: perspectives 10 years after the Women's Health Initiative trials. Climacteric 2012;15:229–34
   PubMed Web of Science ®Google Scholar
• Archer DF, Oger E. Estrogen and progestogen effect on venous thromboembolism in menopausal women. Climacteric 2012;15: 235–40
   PubMed Web of Science ®Google Scholar
• Gompel A, Santen RJ. Hormone therapy and breast cancer risk 10 years after the WHI. Climacteric 2012;15:241–9
   PubMed Web of Science ®Google Scholar
• Barnes EL, Long MD. Colorectal cancer in women: hormone replacement therapy and chemoprevention. Climacteric 2012;15: 250–5
   PubMed Web of Science ®Google Scholar
• Maki PM, Henderson VW. Hormone therapy, dementia, and cognition: the Women's Health Initiative 10 years on. Climacteric 2012;15:256–62
   PubMed Web of Science ®Google Scholar
• de Villiers TJ, Stevenson JC. The WHI: the effect of hormone replacement therapy on fracture prevention. Climacteric 2012; 15:263–6
   PubMed Web of Science ®Google Scholar
• Burger HG, MacLennan AH, Huang K-E, . Evidence-based assessment of the impact of the WHI on women's health. Climacteric 2012;15:281–7
   PubMed Web of Science ®Google Scholar
• Brown S. Shock, terror and controversy: how the media reacted to the Women's Health Initiative. Climacteric 2012;15:275–80
   PubMed Web of Science ®Google Scholar
• Purbrick B, Stranks K, Sum C, . Future long-term trials of postmenopausal hormone replacement therapy – what is possible and what is the optimal protocol and regimen? Climacteric 2012;15:288–93
   PubMed Web of Science ®Google Scholar
• Sturdee DW, Pines A, on behalf of the International Menopause Society Writing Group. Updated IMS recommendations on postmenopausal hormone therapy and preventive strategies for midlife health. Climacteric 2011;14:302–20
   PubMed Web of Science ®Google Scholar
• Writing Group for the North American Menopause Society. Estrogen and progestogen use in postmenopausal women: 2010 position statement of The North American Menopause Society. Menopause 2010;17:242–55
   PubMed Web of Science ®Google Scholar
• Canonico M, Fournier A, Carcaillon L, . Postmenopausal hormone therapy and risk of idiopathic venous thromboembolism: results from the E3N cohort study. Arterioscler Thromb Vasc Biol 2010;30:340–5
   PubMed Web of Science ®Google Scholar
• Renoux C, Dell'Aniello S, Suissa S. Hormone replacement therapy and the risk of venous thromboembolism: a population-based study. J Thromb Haemost 2010;8:979–86
   PubMed Web of Science ®Google Scholar
• The Writing Group for the PEPI Trial. Effects of estrogen on estrogen/progestin regimens on heart disease risk factors in postmenopausal women: The Postmenopausal Estrogen/ Progestin Interventions (PEPI) Trial. JAMA 1995;273:199–208
   PubMed Web of Science ®Google Scholar
• Harman SM, Brinton EA, Cedars M, . KEEPS: The Kronos Early Estrogen Prevention Study. Climacteric 2005;8:3–12
   PubMed Web of Science ®Google Scholar
• ELITE: Early Versus Late Intervention Trial With Estradiol. http://clinicaltrials.gov/ct2/show/NCT00114517
   Google Scholar
• Fournier A, Berrino F, Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res Treat 2008;107:103–11
   PubMed Web of Science ®Google Scholar
• Fournier A, Mesrine S, Boutron-Ruault MC, Clavel-Chapelon F. Estrogen–progestagen menopausal hormone therapy and breast cancer: does delay from menopause onset to treatment initiation influence risks? J Clin Oncol 2009;27:5138–43
   PubMed Web of Science ®Google Scholar
• The Writing Group for the PEPI Trial. Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 1996;275:370–5
   PubMed Web of Science ®Google Scholar